Caroline Seymour

Editor, OncLive®
Caroline Seymour is your initial point of contact for the OncLive® podcast, OncLive On Air™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com

Articles

Telisotuzumab Vedotin Meets Clinical End Points in LUMINOSITY Trial in Previously Treated NSCLC

November 29th 2023

Telisotuzumab vedotin produced meaningful response rates and other clinically relevant outcomes in patients with c-Met protein overexpressed, EGFR wild-type, advanced or metastatic nonsquamous non–small cell lung cancer.

CHMP Supports Approval of Subcutaneous Atezolizumab for All Current IV Indications

November 14th 2023

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of subcutaneous atezolizumab for all indications in which the intravenous formulation is approved, including certain types of lung, liver, bladder, and breast cancer

Research Aims to Make Inroads With CAR T-Cell Therapy in Advanced RCC

November 11th 2023

Although not immediately practice changing, CAR T-cell therapy has the potential to become a standard of care for patients with advanced renal cell carcinoma following progression on checkpoint inhibitors and VEGF inhibitors.

Multimodal Care Marks the Past, Present, and Future of Localized Breast Cancer Management

November 10th 2023

Improvements in screening, systemic therapy, and precision medicine have reduced breast cancer mortality and morbidity, and further progress will hinge on the use of ctDNA and CTCs for disease monitoring, continued development of novel antiestrogenic agents, and movement of ADCs and immunotherapy into expanded settings and indications.

FDA Restricts Approval for Pembrolizumab Plus Trastuzumab and Chemo to Advanced PD-L1+ Gastric/GEJ Cancer

November 9th 2023

The FDA has updated the current indication for pembrolizumab plus trastuzumab, fluoropyrimidine, and platinum-containing chemotherapy for the frontline treatment of patients with locally advanced unresectable or metastatic HER2-positive gastric or GEJ adenocarcinoma to those whose tumors express PD-L1 with a CPS of 1 or more.

Frontline Pyrotinib Plus Trastuzumab and Docetaxel Improves PFS in HER2+ Metastatic Breast Cancer

November 8th 2023

The addition of pyrotinib to trastuzumab and docetaxel led to a significant improvement in progression-free survival compared with placebo plus trastuzumab and docetaxel in patients with newly diagnosed, HER2-positive metastatic breast cancer.

Indirect Treatment Comparison Indicates Improved OS With Brexu-Cel in BTK Inhibitor–Exposed R/R MCL

October 30th 2023

Brexucabtagene autoleucel demonstrated an improvement in overall survival vs standard of care therapy in patients with relapsed/refractory mantle cell lymphoma following prior exposure to a BTK inhibitor, according to data from an indirect treatment comparison of findings from the phase 2 ZUMA-2 trial and retrospective SCHOLAR-2 trial.

Breaking Ground in Breast, Lung, Gynecologic, and Gastrointestinal Cancers From ESMO 2023: Drs Tarantino, Sands, Vergote, and Janjigian

October 24th 2023

OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ESMO Congress. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

Frontline Amivantamab Plus Lazertinib Bests Osimertinib in Advanced EGFR+ NSCLC

October 23rd 2023

The combination of amivantamab and lazertinib reduced the risk of disease progression or death by 30% compared with osimertinib alone as frontline therapy for patients with advanced non–small cell lung cancer harboring classical EGFR sensitizing mutations.

Gathering Insights in Gastrointestinal Cancers From ESMO 2023: Dr Pietrantonio

October 22nd 2023

Tisotumab Vedotin Improves Survival in Recurrent/Metastatic Cervical Cancer

October 22nd 2023

Tisotumab vedotin led to a 30% reduction in the risk of death vs investigator’s choice of chemotherapy as second- or third-line therapy in patients with recurrent or metastatic cervical cancer with disease progression on doublet chemotherapy.

Looking at Novel Treatments in Lung and Genitourinary Cancers From ESMO 2023: Drs Janne and Bastos

October 21st 2023

Amivantamab Plus Chemotherapy Nearly Doubles PFS in EGFR Exon 20–Mutant NSCLC

October 21st 2023

The combination of amivantamab-vmjw (Rybrevant) and chemotherapy produced a median progression-free survival of 11.4 months vs 6.7 months with chemotherapy alone in patients with advanced, EGFR exon 20 insertion–positive non–small cell lung cancer.

Sacituzumab Govitecan Demonstrates Modest Activity in Pretreated HNSCC

October 21st 2023

Sacituzumab govitecan-hziy led to modest but durable antitumor activity with predominant gastrointestinal toxicities in patients with metastatic or locally recurrent head and neck squamous cell carcinoma who received between 1 and 3 prior lines of therapy.

Understanding Unprecedented Data in Genitourinary Cancers From ESMO 2023: Dr Powles

October 20th 2023

EMA Grants Orphan Drug Designation to LSTA1 for Pancreatic Cancer

October 17th 2023

The European Medicines Agency’s Committee for Orphan Medical Products has granted orphan drug designation to LSTA1 for the treatment of patients with pancreatic cancer.

European Commission Approves Adjuvant Pembrolizumab for High-Risk NSCLC

October 16th 2023

The European Commission has approved pembrolizumab as adjuvant monotherapy for the treatment of adult patients with non–small cell lung cancer who are at high risk of recurrence following complete resection and platinum-based chemotherapy.

Venetoclax Elicits Responses in B-Cell Receptor–Pretreated CLL Regardless of Mutation Status

October 9th 2023

Treatment with single-agent venetoclax led to prolonged disease response in patients with chronic lymphocytic leukemia who had relapsed or become refractory to prior B-cell receptor inhibitors including ibrutinib and idelalisib, according to findings from a phase 2 study.

Ibrutinib Cessation Following Prolonged Exposure Supports Intermittent Investigation in CLL

October 8th 2023

Stable peripheral disease levels lasting 12 months were reported in patients with treatment-naïve chronic lymphocytic leukemia following 6 years of continuous treatment with ibrutinib.

Radiotherapy-Activated NBTXR3 Elicits Activity in Older/Comorbid Locally Advanced HNSCC

October 6th 2023

Treatment with the first-in-class radioenhancer NBTXR3 proved tolerable and effective in older patients with advanced head and neck squamous cell carcinoma and a comorbidity index.